New law requires the La. Medicaid program to provide coverage for a continuous glucose monitor for the treatment of an enrollee who has any type of diabetes with the use of insulin more than two times daily or evidence of level 2 or level 3 hypoglycemia or who has glycogen storage disease type 1a.

New law requires an enrollee who receives coverage for a continuous glucose monitor to attend regular follow-up visits with a healthcare provider at a minimum of every six months to assess the ongoing benefit of the enrollee's use of a continuous glucose monitor.

New law requires the La. Dept. of Health to implement the coverage requirement of new law using the most cost-effective solution available to the department.

Effective August 1, 2022.

(Adds R.S. 46:450.8)